Register Login

TEMPEST THERAPEUTICS, INC. (TPST)

(80% Positive) TEMPEST THERAPEUTICS, INC. (TPST) Announces Enrollment Update for replicated Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 6, 2026, 11:46 a.m.

    📋 TEMPEST THERAPEUTICS, INC. (TPST) - Clinical Trial Update

    Filing Date: 2026-05-06

    Accepted: 2026-05-06 07:45:44

    Event Type: Clinical Trial Update

    Event Details:

    TEMPEST THERAPEUTICS, INC. (TPST) Announces Clinical Trial Update TEMPEST THERAPEUTICS, INC. (TPST) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: replicated, Meeting
    • Diseases/Conditions: registrational trial, Dublin
    • Clinical Stage: Phase 1 trial, Phase 1
    • Collaboration: ICANS
      • targeting CAR-T pipeline programs. Earlier this year, Tempest announced positive interim data from REDEEM-1, including a 100% complete response (“CR”) rate among all six efficacy then-evaluable patients according to the International Myeloma Working Group (“IMWG”) uniform response criteria, as well as a favorable safety profile. Today’s clinical update more than doubles the previous dataset, achieving a 100% CR rate among all 15 CAR-T-naïve efficacy evaluable patients across two ongoing Phase 1 trials – REDEEM-1 evaluating TPST-2003
      • targeting CAR architecture in patients with rrMM, including in patients with extramedullary disease (“EMD”) • Median progression free survival of 23.1 months, including in patients with EMD, if replicated in registrational trial, would position TPST-2003
      • targeting CAR-T therapies, in particular in patients with EMD” said Dr. Matt Angel, President and Chief Executive Officer of Tempest. “We are excited by the potential to offer patients who have relapsed from multiple prior lines of therapy a treatment that may achieve up to complete remission of their cancer.” The observed safety profile (no Grade >3 CRS or ICANS), together with the consistency of responses observed in the REDEEM-1 trial continue to support Tempest’s plan to pursue its objective of meeting with the FDA to discuss initiating a U.S. registrational study later this year. Presentation Details REDEEM-1, a multicenter open-label Phase 1/2a study of a BCMA/CD19 dual-targeting CAR-T therapy in patients with relapsed/refractory multiple myeloma including those with extramedullary disease. Abstract #1268

    🔬 Clinical Development Pipeline (TEMPEST THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Part 4 TPST-1120 + nivolumab Other Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Part 3 TPST-1120 Other Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Part 2 TPST-1120 + nivolumab Other Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Part 1 TPST-1120 Other Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Bevacizumab Other Phase PHASE3 Hepatocellular Carcinoma (HCC) ClinicalTrials.gov
    Atezolizumab Other Phase PHASE3 Hepatocellular Carcinoma (HCC) ClinicalTrials.gov
    TPST-1120 Other Phase PHASE3 Hepatocellular Carcinoma (HCC) ClinicalTrials.gov
    Pembrolizumab Other Phase PHASE1 Solid Tumor ClinicalTrials.gov
    TPST-1495 once daily or on intermittent schedule Other Phase PHASE1 Solid Tumor ClinicalTrials.gov
    TPST-1495 twice daily Other Phase PHASE1 Solid Tumor ClinicalTrials.gov
    IO-108 1200 mg DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    NKT2152 DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    IO-108 1800 mg DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    ADG126 DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    Tobemstomig 1200 mg DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    Tobemstomig 600 mg DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    Bevacizumab 10 mg/kg DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    Tobemstomig 2100 mg DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    Tocilizumab DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    Tiragolumab DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov
    Bevacizumab 15 mg/kg DRUG Phase PHASE1 Advanced Liver Cancers ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: TEMPEST THERAPEUTICS, INC.
    • Ticker Symbol: TPST

Search

News categories